Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


QUOTED. 8 October 2019. Mary Anne Heino.

Executive Summary

Diagnostic imaging agent company Lantheus Holdings will acquire Progenics Pharmaceuticals, the developer of radiotherapeutics and imaging agents to treat cancer, in an all-stock deal announced last week. See what Lantheus CEO Mary Anne Heino said about the deal here.

“The combination of Lantheus and Progenics has a clear and compelling rationale. This transaction leverages our core capabilities, including proven commercial and operational expertise while diversifying our revenue streams by broadening our presence in emerging uses of radioisotopes in precision diagnostics, as well as the exciting field of radiopharmaceuticals in oncology treatment.” – Mary Anne Heino, CEO, Lantheus Holdings Inc.

Click here for a free trial of Medtech Insight


Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts